The diagnostic test, which has been validated in breast, lung, colorectal, skin, and prostate cancers, requires sample submission to Guardant's CLIA-certified laboratory. The test, currently priced at $4900, maybe covered by payers where genomic profiling is needed and conventional biopsy is not an option.